| Literature DB >> 19625154 |
Séverine Lamon1, Sylvain Giraud, Léonie Egli, Jessica Smolander, Michael Jarsch, Kay-Gunnar Stubenrauch, Alice Hellwig, Martial Saugy, Neil Robinson.
Abstract
C.E.R.A., a continuous erythropoietin receptor activator, is a new third-generation erythropoiesis-stimulating agent (ESA) that has recently been linked with abuse in endurance sports. In order to combat this new form of doping, we examined an enzyme-linked immunosorbent assay (ELISA) designed to detect the presence of C.E.R.A. in serum samples. The performance of the assay was evaluated using a pilot excretion study that involved six subjects receiving C.E.R.A. Validation data demonstrated an excellent reproducibility and ensured the applicability of the assay for anti-doping purposes. To maximize the chances of detecting the drug in serum samples, we propose the use of this specific ELISA test as a high-throughput screening method, combined with a classic isoelectric focusing test as a confirmatory assay. This strategy should make C.E.R.A. abuse relatively easy to detect, thereby preventing the future use of this drug as a doping agent.Mesh:
Substances:
Year: 2009 PMID: 19625154 DOI: 10.1016/j.jpba.2009.06.038
Source DB: PubMed Journal: J Pharm Biomed Anal ISSN: 0731-7085 Impact factor: 3.935